Filing Signals

Source: SEC EDGAR Compiled 2026-11-13 17:17 UTC 23 automated checks passing

← All events

InMed Pharmaceuticals Inc.

CIK 1728328 INM·Pharmaceutical Preparations · All EDGAR filings ↗

Progression

  1. Going concern 10-K
  2. Finance chief departure 8-K +62d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Finance chief departure elevated Filing comparison

InMed Pharmaceuticals Inc.'s Chief Financial Officer departed, replaced on an interim basis

Evidence
Interim only
Yes
Item code
5.02
Item title
Departure of Directors or Certain Officers
Role
Chief Financial Officer
Severity
elevated
Source
SEC 8-K item code
Successor named
No
Why
The company's chief financial or accounting officer departed, disclosed under 8-K Item 5.02.

Source filing ↗

Going concern Filing comparison

InMed Pharmaceuticals Inc. disclosed substantial doubt about its ability to continue as a going concern

No going-concern disclosure → Substantial doubt about ability to continue as a going concern

Explanatory Paragraph – Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1, the Company has a significant working capital deficiency, has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do…
Evidence
Blank check
No
Comparable
Yes
Current state
substantial_doubt
Current state label
Substantial doubt about ability to continue as a going concern
Direction
escalated
Located in
going-concern note
Prior filed
2025-10-24
Prior form
10-K/A
Prior state
none
Prior state label
No going-concern disclosure
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.

Source filing ↗ Prior filing ↗